NetScientific healthcare technology group

NetScientific is a transatlantic healthcare IP commercialisation group.
We fund and develop companies that significantly improve the health and well-being of people with chronic diseases.

Our Portfolio

Targeting chronic diseases

Glycotest

Core Portfolio, Diagnostics

Glycotest Glycotest is a US-based liver diagnostics company seeking to commercialise …

ProAxsis

Core Portfolio, Diagnostics

ProAxsis ProAxsis is a medical diagnostics company based in Northern Ireland, …

PDS Biotechnology

Core Portfolio, Therapeutics

PDS Biotechnology PDS is a clinical stage immunotherapy company developing a …

G-Tech Medical

Digital health, Seed Portfolio

G-Tech Medical G-Tech Medical is developing a wireless, wearable, disposable patch …

Neumitra

Digital health, Seed Portfolio

Neumitra Neumitra develops embedded biomodules to accurately and continuously measure how …

Longevity Biotech

Seed Portfolio, Therapeutics

Longevity Biotech Overview Longevity Biotech (LBT) is developing a new class …

Epibone

Seed Portfolio, Therapeutics

Epibone EpiBone’s pioneering technology uses a scan of the patient’s bone …

Cytovale

Microfluidics, Seed Portfolio

Cytovale CytoVale is pioneering a new class of biomarkers. Disease states …

See our Portfolio

OUR TEAM

Sector-specialist senior management team with extensive commercial experience.

Sir Richard Sykes, FRS
Sir Richard Sykes, Non-Executive Chairman of the Group, joined NetScientific in 2008. Sir Richard spent thirty years working in the biotechnology and pharmaceutical industries, …

Sir Richard Sykes, FRS
Chairman
Ian Postlethwaite
Ian Postlethwaite, Chief Executive Office, Chief Financial Officer & Company Secretary, joined NetScientific in June 2016. He brings over 14 years of biopharma experience …

Ian Postlethwaite
Chief Executive Officer, Chief Financial Officer & Company Secretary

See our Team

NEWS

Glycotest receives 2nd $3m tranche of $10m finance

Nov 21, 2019

Glycotest, News, RNS Announcements

NetScientific plc (“NetScientific” or the “Company”) Portfolio Company Glycotest Inc. receives the second $3 million tranche of the $10 million Series A financing London, UK …

5 MIN READ

Appointment to the Board

Oct 14, 2019

News, RNS Announcements

NetScientific plc (“NetScientific” or the “Company”) Appointment to the Board London, UK – 14 October 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, …

2 MIN READ

PDS collaborates with Merck in Phase 2 studies

Oct 3, 2019

News, PDS Biotechnology, RNS Announcements

NetScientific plc (“NetScientific” or the “Company”) Portfolio Company PDS Biotechnology collaborates with Merck in Phase 2 studies for PDS0101 in metastatic head and neck cancer and high-risk …